Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Journal Articles

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Blood (2023) 142 (Supplement 1): 105.

https://doi.org/10.1182/blood-2023-180952

Published: 2023

Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser

Blood (2023) 142 (Supplement 1): 225.

https://doi.org/10.1182/blood-2023-181007

Published: 2023

Journal Articles

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Mazyar Shadman, Brian G Till, Vikram Raghunathan, Edus H Warren, Jordan Gauthier, Stephen D Smith, Taran Gujral, Chihiro Morishima, Qian Wu, Jenna M Voutsinas, Amy Sperling, Joshua Dizon, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2023-183034

Published: 2023

Journal Articles

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood (2022) 139 (26): 3722–3731.

https://doi.org/10.1182/blood.2021014497

Published: 2022

Includes: Supplemental data

Journal Articles

Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy

Jennifer L. Crombie, Robert A. Redd, Victor A. Chow, Jordan Gauthier, Erin Mullane, Geoffrey Shouse, Alex F. Herrera, Jason Romancik, Jonathon B. Cohen, Anna Saucier, Roch Houot, Caron Jacobson, Philippe Armand, Brian T. Hess

Blood (2021) 138 (Supplement 1): 886.

https://doi.org/10.1182/blood-2021-152819

Published: 2021

Journal Articles

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 2816.

https://doi.org/10.1182/blood-2021-147454

Published: 2021

Journal Articles

Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel

Blood (2021) 138 (Supplement 1): 1756.

https://doi.org/10.1182/blood-2021-153277

Published: 2021

Journal Articles

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

Lorena Panaite, MBBS, Jordan Gauthier, MD, Paula Perkins, MS,PA-C, Jenna Voutsinas, MPH, Qian Vicky Wu, PhD, Angela Kirk, PA-C, Aisling Cearley, PA-C, Erin Mullane, DNP, Ryan D. Cassaday, MD, Hans-Peter Kiem, MDPhD, Victor A. Chow, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD, Brian G. Till, MD, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Mazyar Shadman, MDMPH

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134816

Published: 2020

Journal Articles

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 2889.

https://doi.org/10.1182/blood-2019-124962

Published: 2019

Journal Articles

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Elizabeth Loggers, MD PhD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 413.

https://doi.org/10.1182/blood-2019-124857

Published: 2019

Journal Articles

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Victor A. Chow, MD, Paul S. Martin, MD, Stephen D. Smith, MD, Brian G. Till, MD, Solomon A. Graf, MD, Kerstin L. Edlefsen, MD, Lindsay M. Hannan, MD MSPH, Elahe A. Mostaghel, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5254.

https://doi.org/10.1182/blood-2019-125462

Published: 2019

Journal Articles

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

Mazyar Shadman, MD, Jordan Gauthier, MD MSc, Sirin Khajavian, MD, Alexandre V. Hirayama, MD, Ryan C. Lynch, MD, Stephen D. Smith, MD, Chaitra S. Ujjani, MD, Victor A. Chow, MD, Hans-Peter Kiem, MD PhD, Brian G. Till, MD, Ajay K. Gopal, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 4294.

https://doi.org/10.1182/blood-2019-126269

Published: 2019

Journal Articles

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Manoj P. Menon, MD, Victor A. Chow, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Andrei Shustov, MD, Stephen D. Smith, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Chaitra S. Ujjani, MD, Thomas S. Uldrick, MD MS, Edus H. Warren, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4733.

https://doi.org/10.1182/blood-2019-127505

Published: 2019

Journal Articles

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Prathima Reddy, MD, Alexandra Sokolova, MD, Victor A. Chow, MD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Brian G. Till, MD, Andrei R Shustov, MD, Edus H. Warren, MD PhD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Yolanda D. Tseng, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2018) 132 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2018-99-119794

Published: 2018

Journal Articles

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Victor A. Chow, MD, Ajay K. Gopal, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R. Shustov, MD, Manoj P. Menon, MD, Sandra Kanan, MSN, ARNP, Utkarsh H. Acharya, DO, Erin Mullane, DNP, Lindsay M. Hannan, MD MS, Jenna M. Voutsinas, MSc, Ted Gooley, PhD, Ryan C. Lynch, MD

Blood (2018) 132 (Supplement 1): 94.

https://doi.org/10.1182/blood-2018-99-110747

Published: 2018

Journal Articles

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma

Victor A. Chow, Mazyar Shadman, Ajay K. Gopal

Blood (2018) 132 (8): 777–781.

https://doi.org/10.1182/blood-2018-04-839217

Published: 2018

Journal Articles

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Victor A. Chow, MD, Joseph Rajendren, MD, Andrew Shields, MD, Darrell R. Fisher, PhD, Frederick R. Appelbaum, MD, Ryan D. Cassaday, MD, Andrew J. Cowan, MD, Paul J. Martin, MD, Leona Holmberg, MD PhD, Ted Gooley, PhD, Philip A. Stevenson, MS, John M. Pagel, MD PhD, Damian J. Green, MD, Oliver W. Press, MD PhD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2018.

https://doi.org/10.1182/blood.V130.Suppl_1.2018.2018

Published: 2017

Journal Articles

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Victor A. Chow, Kathleen Shannon Dorcy, RN, MN, Ph.C, Stephen H. Petersdorf, MD, Kelda M. Gardner, PA-C, Pamela S. Becker, MD, PhD, Roland B. Walter, MD, PhD, John M. Pagel, MD, PhD, Paul C. Hendrie, MD, PhD, Andrei R. Shustov, MD, Janis L. Abkowitz, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD

Blood (2010) 116 (21): 3806.

https://doi.org/10.1182/blood.V116.21.3806.3806

Published: 2010

NARROW

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Lisocabtagene Maraleucel as Second-Line Therapy for R/R Large B-Cell Lymphoma in Patients Not Intended for Hematopoietic Stem Cell Transplant: Final Analysis of the Phase 2 PILOT Study

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Eligibility for Car-T Trials: An Analysis of Selection Criteria and Survival Outcomes in Chemorefractory DLBCL

Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma

A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma

Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only